Barclays PLC Igm Biosciences, Inc. Transaction History

Barclays PLC

$357 Billion
Q4 2024

A detailed history of Barclays PLC transactions in Igm Biosciences, Inc. stock. As of the latest transaction made, Barclays PLC holds 26,303 shares of IGMS stock, worth $37,613. This represents 0.0% of its overall portfolio holdings.

Number of Shares

26,303

Previous 21,554 22.03%

Holding current value

$37,613

Previous $356,000 55.06%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$6.05 - $17.83 $28,731 - $84,674	4,749 Added 22.03%	26,303 $160,000
Q3 2024 Nov 15, 2024	BUY	$6.28 - $17.68 $44,129 - $124,237	7,027 Added 48.37%	21,554 $356,000
Q2 2024 Aug 14, 2024	SELL	$6.51 - $11.47 $29,470 - $51,924	-4,527 Reduced 23.76%	14,527 $101,000
Q1 2024 May 15, 2024	SELL	$8.68 - $17.36 $47,878 - $95,757	-5,516 Reduced 22.45%	19,054 $184,000
Q4 2023 Feb 15, 2024	BUY	$3.94 - $8.79 $67,898 - $151,478	17,233 Added 234.88%	24,570 $204,000
Q3 2023 Nov 07, 2023	SELL	$6.66 - $10.64 $1,545 - $2,468	-232 Reduced 3.07%	7,337 $62,000
Q2 2023 Aug 03, 2023	SELL	$8.86 - $14.0 $6,113 - $9,660	-690 Reduced 8.35%	7,569 $70,000
Q1 2023 May 04, 2023	BUY	$13.74 - $25.76 $34,322 - $64,348	2,498 Added 43.36%	8,259 $113,000
Q4 2022 Feb 13, 2023	BUY	$15.45 - $26.02 $58,864 - $99,136	3,810 Added 195.28%	5,761 $97,000
Q3 2022 Nov 03, 2022	SELL	$15.42 - $27.01 $111,887 - $195,984	-7,256 Reduced 78.81%	1,951 $44,000
Q2 2022 Aug 12, 2022	SELL	$13.27 - $25.5 $2,136 - $4,105	-161 Reduced 1.72%	9,207 $166,000
Q1 2022 May 16, 2022	BUY	$13.42 - $29.73 $125,718 - $278,510	9,368 New	9,368 $251,000

Others Institutions Holding IGMS

# of Institutions

Shares Held

19.8M

Call Options Held

75K

Put Options Held

35.9K

View Full List

About IGM Biosciences, Inc.

Ticker IGMS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,969,000
Market Cap $41.4M
Description
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...

More about IGMS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account